Genitourinary Cancer News

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of new precision medicine therapies in prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of JNJ-6520 in prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of three studies into quality-of-life outcomes in metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of the CYCLONE 2 study into metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a phase 1/phase 2 study into proteolysis-targeting chimeras in prostate cancer treatment, presented at ASCO Annual Meeting.

People with type 2 diabetes who use a GLP-1 receptor agonist have a lower risk for 10 types of obesity-associated cancer compared with those who use insulin, according to data published in JAMA Network Open.

Individuals with therapy-refractory cancer who received waivers to participate in a clinical trial for off-label targeted therapies achieved similar clinical benefits as those who took part in the study without an exception.

The combination of durvalumab and chemotherapy improved outcomes compared with neoadjuvant chemotherapy alone for patients with muscle-invasive bladder cancer, according to the agent’s manufacturer.

Discussion about lung cancer research breakthroughs dominated the social media conversation among health care professionals during this year’s ASCO Annual Meeting.

A new clinic at The Ohio State University — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Pelotonia Institute for Immuno-Oncology seeks to minimize the autoimmune effects of immunotherapy cancer treatment.